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The transcription factor NF-B is essential for 
liver homeostasis, as it is involved in control-
ling  the  balance  between  survival  and  death 
signals (Luo et al., 2005). Upon ligand binding, 
distinct receptors stimulate the IKK complex 
(IKK1/IKK, IKK2/IKK, and IKK/NEMO), 
which initiates NF-B activation. The regu-
latory subunit IKK/NEMO is crucial dur-
ing this process, as NEMO deletion results 
in complete NF-B inhibition and embry-
onic lethality.
Hepatocyte-specific deletion of NEMO and 
its consequent NF-B inhibition has detrimen-
tal effects on liver homeostasis, as it promotes 
spontaneous  steatohepatitis,  fibrosis  progres-
sion, and development of hepatocellular carci-
noma (HCC; Luedde et al., 2007). Additionally, 
NEMO  deletion  in  hepatocytes  promotes   
severe TNF-mediated liver damage (Beraza   
et al., 2007). However, the impact of other TNF- 
related cytokines on acute liver injury and their 
contribution to the development of the strong 
parenchymal damage observed in hepatocyte-
specific NEMO-deleted (NEMOhepa) mice 
remains unknown.
FasL and TNF-related apoptosis-inducing 
ligand (TRAIL) belong to the TNF family of 
cytokines, as they signal through death recep-
tors which contain cytoplasmic death domains 
(Schutze et al., 2008). Activation of the FasL/Fas 
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Nuclear factor B (NF-B) is one of the main transcription factors involved in regulating 
apoptosis, inflammation, chronic liver disease, and cancer progression. The IKK complex 
mediates NF-B activation and deletion of its regulatory subunit NEMO in hepatocytes 
(NEMOhepa) triggers chronic inflammation and spontaneous hepatocellular carcinoma 
development. We show that NEMOhepa mice were resistant to Fas-mediated apoptosis but 
hypersensitive to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) as the 
result of a strong up-regulation of its receptor DR5 on hepatocytes. Additionally, natural 
killer (NK) cells, the main source of TRAIL, were activated in NEMOhepa livers. Interestingly, 
depletion of the NK1.1+ cells promoted a significant reduction of liver inflammation and an 
improvement of liver histology in NEMOhepa mice. Furthermore, hepatocyte-specific NEMO 
deletion strongly sensitized the liver to concanavalin A (ConA)–mediated injury. The critical 
role of the NK cell/TRAIL axis in NEMOhepa livers during ConA hepatitis was further con-
firmed by selective NK cell depletion and adoptive transfer of TRAIL-deficient/ mono-
nuclear cells. Our results uncover an essential mechanism of NEMO-mediated protection of 
the liver by preventing NK cell tissue damage via TRAIL/DR5 signaling. As this mechanism is 
important in human liver diseases, NEMOhepa mice are an interesting tool to give insight 
into liver pathophysiology and to develop future therapeutic strategies.
© 2009 Beraza et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Figure 1.  Hepatocyte-specific NEMO-deleted mice (NEMOhepa) are protected against Fas-mediated apoptosis. (A) Survival curve after i.p. 
injection of 0.5 µg/g Jo2, evidencing the resistance of NEMOhepa mice to Fas-mediated death. (B–D) Macroscopic view of livers 3 h after Jo2 (B), liver 
weight/body weight ratio (B), serum transaminases (C), and H&E staining (D) showed fulminant hepatitis in NEMOf/f mice after Jo2, whereas NEMOhepa JEM VOL. 206, August 3, 2009  1729
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remained unaffected. (E and F) TUNEL (E) and caspase 8 and 3 (F) activity analysis confirmed Jo2 apoptosis. Activity is represented in times versus un-
treated NEMOf/f. (G and H) Fas mRNA and IHC analysis in whole liver (G) and isolated primary hepatocytes (H) showed stronger expression in WT com-
pared than in NEMOhepa mice. (I) TNF mRNA and cellular location indicated by IHC. (J) Western blotting showed phosphorylation of JNK1 (p45) and JNK2 
(p54) in NEMOf/f mice after Jo2. JNK1 and GAPDH act as loading controls. Bars, 50 µm. Data are representative of three independent experiments. n = 4.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001 (NEMOf/f vs. NEMOhepa). §§, P < 0.01; §§§, P < 0.001 (NEMOf/f vs. Jo2/NEMOf/f). Error bars represent SD.
 
system leads to massive apoptotic cell death and fulminant 
hepatitis (Ogasawara et al., 1993). More recently, liver steatosis 
has been shown to hypersensitize hepatocytes to Fas-mediated 
apoptosis, contributing to the progression of steatohepatitis 
and end-stage liver disease (Zou et al., 2007).
TRAIL, via its receptor DR5, selectively induces apopto-
sis of transformed and virally infected hepatocytes, and NF-B–
dependent signaling counteracts its detrimental effects (Luo 
et al., 2004). The cellular responses to TRAIL have been re-
lated to the inflammatory status of the liver, and DR5 up-
regulation can be mediated by free fatty acids and bile acids, 
indicating a link between fat metabolism and TRAIL signal-
ing (Higuchi et al., 2004; Malhi et al., 2007). This is supported 
by findings showing high levels of liver DR5 expression in 
nonalcoholic steatohepatitis patients (Malhi et al., 2007). Ad-
ditionally, fatty liver disease activates the innate immune sys-
tem by triggering NKT cells, promoting an unbalanced Th1/Th2 
response in the liver (Guebre-Xabier et al., 2000). This con-
tributes to create a proinflammatory environment where high 
IFN- expression is found. Furthermore, IFN- produced 
by activated NKT cells strongly induces NK cells to express 
TRAIL (Smyth et al., 2001).
Together, these data suggest that FasL and TRAIL could be 
involved in mediating the severe liver phenotype observed in 
NEMOhepa mice. In the present study, we aimed to character-
ize the implication of these cytokines and to uncover the patho-
physiological mechanisms contributing to liver inflammation 
and further disease progression in NEMOhepa animals.
We demonstrate that NEMOhepa mice are resistant to 
Fas-mediated apoptosis, whereas they are hypersensitive to 
TRAIL-mediated cell death. Moreover, we highlight an es-
sential role for NK cells, the main producers of TRAIL, in 
the spontaneous phenotype observed in NEMOhepa mice, as 
interfering with this cascade significantly improved liver ho-
meostasis and attenuated the impact of T cell–mediated hepa-
titis in NEMOhepa mice.
RESULTS AND DISCUSSION
To better characterize the role of NEMO in hepatocytes, we 
generated NEMO loxP mice and crossed them with alfp-Cre 
transgenic animals to create NEMOf/f (WT) and NEMOhepa 
(KO) mice (Fig. S1, A and B). Hepatocyte-specific NEMO 
deletion led to a complete lack of NF-B activation after TNF 
stimulation, confirming our previous results (Fig. S1 C; Luedde 
et al., 2007). Additionally, in consonance with our previous 
data (Luedde et al., 2007), NEMOhepa animals exhibited 
spontaneously elevated TNF and TNFR1 levels, although no 
significant  differences  were  found  in  TNFR2  expression 
(Fig. S1 D). Immunohistochemistry (IHC) confirmed higher 
TNF expression in the nonparenchymal cell compartment   
in NEMOhepa mice (Fig. S1 D). Moreover, 12-wk-old 
NEMOhepa mice displayed high ALT levels (Fig. S1 E), ac-
companied by signs of nonalcoholic steatohepatitis, activa-
tion of progenitor cells, profuse inflammation, and features of 
chronic liver damage such as hepatocyte dysplasia and aniso-
karyosis (Fig. S1 F, top). The combination of these events 
contributed to HCC development in 1-yr-old NEMOhepa 
mice, as indicated by liver tumors and higher liver weight/
body weight ratio (Fig. S1, F [bottom] and G).
Hepatocyte-specific  NEMO  deletion  promotes  hyper-
sensitivity to exogenously administered TNF; however, the 
animals survived this challenge (Beraza et al., 2007). As NEMO 
deletion may also contribute to amplifying liver damage trig-
gered by other TNF-related cytokines, we sought to investi-
gate their implication in mediating the liver phenotype of 
NEMOhepa mice.
Fas activation promotes acute hepatic failure (Ogasawara 
et al., 1993). Hence, stimulation with an anti-Fas mAb (Jo2, 
0.5 µg/g) resulted in the death of all NEMOf/f mice within 10 h 
(Fig. 1 A). Unexpectedly, NEMOhepa animals were less sensi-
tive to Jo2, as 90% of the mice survived (Fig. 1 A). Macro-
scopic  view  confirmed  that  NEMOhepa  livers  remained 
unaffected while NEMOf/f showed significant blood accumu-
lation and a higher liver weight/body weight ratio (Fig. 1 B). 
Accordingly, NEMOf/f mice showed clear signs of fulminant 
hepatitis, as high ALT levels, infiltrating PMN and RBC, ne-
crosis, and apoptotic bodies were observed (Fig. 1, C and D). 
In contrast, we failed to detect any significant effects of Jo2 in 
NEMOhepa mice, as only the preexisting elevated ALT levels 
and parenchymal damage, caused by the spontaneous pheno-
type of these mice, was observed (Fig. 1, C and D). TUNEL 
assay, caspase 8, and caspase 3 activity confirmed resistance to 
Fas-induced apoptosis in NEMOhepa mice (Fig. 1, E and F).
These data may seem contradictory to reports showing 
that NF-B inhibition sensitizes hepatocytes to Fas apoptosis 
(Hatano et al., 2000). However, as we previously described, 
NF-B is one of the main factors responsible for activating 
Fas transcription (Kuhnel et al., 2000). Thus, we hypothe-
sized that NEMOhepa mice might have a defective turnover 
of this receptor, thereby promoting resistance to Jo2 apopto-
sis. In agreement with this, NEMOhepa mice exhibited re-
duced levels of Fas (25% less) and impaired up-regulation of 
Fas after Jo2 (Fig. 1 G). IHC confirmed these results, as Fas 
staining was almost negative on NEMOhepa mice after Jo2 
(Fig. 1 G). Messenger RNA (mRNA) analysis on isolated 
primary hepatocytes corroborated the inability of NEMOhepa 
mice to express Fas (Fig. 1 H), which led to impaired NF-B 
activation on these cells (not depicted).1730 NEMO MODULATES LIVER NK/NKT CELL ACTIVATION | Beraza et al.
NEMOhepa livers had significantly reduced numbers   
of NK and NKT cells compared with NEMOf/f littermates 
(Fig. 3 A). As NK cells’ activation is associated with their 
apoptosis, the lower NK1.1+ cell number found in NEMOhepa 
livers could reflect their activation. Hence, NK1.1+ cells from 
NEMOhepa mice exhibited significantly higher levels of   
annexin V when compared with NEMOf/f mice (Fig. 3 B). 
Activation of NK cells involves strong production of proin-
flammatory cytokines, like IFN- and IL-12, promoting their 
cytotoxic activity and apoptosis (Vivier et al., 2008). Accord-
ingly, we found higher IFN- and IL-12 (p35) expression as-
sociated with lower IL-4 levels in NEMOhepa mice compared 
with WT littermates. Additionally, higher CCL5 (RANTES) 
levels found in NEMOhepa livers (Fig. 3 C) may reflect a com-
pensatory response to restore liver NK cells number (Morris 
and Ley, 2004). These data were confirmed on isolated NK1.1+ 
cells from livers of NEMOhepa mice showing higher IFN- 
and CCL5 but lower IL4 levels (Fig. 3 D). FACS and mRNA 
analysis evidenced strong TRAIL expression on liver NK1.1+ 
cells from NEMOhepa compared with WT mice (Fig. 3 E).
These data suggest that hepatocyte-NEMO deletion cor-
relates with an altered NK/NKT cell response. Moreover, the 
proclivity of TRAIL-producing NK cells to promote cytotox-
icity against self-hepatocytes (Ochi et al., 2004) appears to be 
enhanced in NEMOhepa mice, suggesting that this may repre-
sent a potential mechanism involved in the chronic inflamma-
tion and parenchymal damage observed in NEMOhepa mice.
To test this hypothesis, we investigated the potential ben-
eficial effects of NK/NKT cell inactivation in NEMOhepa 
mice by using a NK1.1 mAb (PK-136). FACS and mRNA 
analysis confirmed efficient cell depletion after NK1.1 mAb 
administration (Fig. 3 F) that attenuated IFN- and CCL5 
expression, correlating with strong amelioration of liver dam-
age in NEMOhepa mice (Fig. 3, H and I). FACS analysis 
confirmed the attenuation of the proinflammatory environ-
ment in NK1.1 mAb-treated NEMOhepa mice, as a signifi-
cant reduction of CD11b+ cells was detected (Fig. 3 J).
Based on our present data, which identify the critical det-
rimental role of NK1.1+ cells in the pathogenesis of liver in-
jury in NEMOhepa mice (Fig. 3), we further characterized 
the contribution of these cells during concanavalin A (ConA) 
hepatitis, where NKT cells activation have a major implica-
tion (Toyabe et al., 1997; Takeda et al., 2000).
Administration of 15 mg/kg ConA caused 100% mortality 
of NEMOhepa mice within 16 h, whereas all NEMOf/f mice 
survived (Fig. S3). To better define the molecular mechanism 
leading to the mortality of NEMOhepa mice, we next admin-
istered 25 mg/kg ConA and sacrificed the animals 6 h after in-
jection. ConA triggered a more severe hepatitis in NEMOhepa 
mice compared to NEMOf/f littermates. Massive destruction 
of liver parenchyma in NEMOhepa mice were indicated by 
high ALT, strong inflammation, and necrotic and apoptotic 
cell death (Fig. 4, A–C). Moreover, ConA induced signifi-
cantly higher levels of IFN-, IL-4, and CCL5 in NEMOhepa 
compared with NEMOf/f livers (Fig. 4 D). ELISA confirmed 
systemic IFN- elevation (Fig. 4 E).
Additionally,  in  accordance  with  the  observation  that 
Jo2/Fas induces TNF expression through NF-B activation 
(Lu et al., 2002), we found a strong up-regulation of TNF in 
NEMOf/f mice after Jo2 (43-fold), whereas it was barely reg-
ulated in NEMOhepa mice (Fig. 1 I). IHC on liver sections 
confirmed macrophages as the main source of TNF after Fas 
activation, which likely explains the modest TNF regulation 
observed in NEMOhepa mice (Fig. 1 I).
Finally, NEMOf/f mice displayed strong c-Jun N-termi-
nal kinase (JNK) phosphorylation, whereas it remained inac-
tive in NEMOhepa mice after Jo2 (Fig. 1 J), supporting the 
absence of cellular stress in our KO animals upon Fas activa-
tion. These results suggest that Fas is not an essential mediator 
of the pathogenesis observed in NEMOhepa mice.
Thus,  we  next  investigated  the  potential  implication  of 
TRAIL in the initiation and progression of chronic liver dam-
age in our NEMO-deficient mice. As expected, low doses of 
TRAIL had no effect on NEMOf/f mice, as ALT levels and 
liver architecture remained unaffected (Fig. 2, A and B). In clear 
contrast, TRAIL had a strong impact on NEMOhepa mice, as a 
significant rise in serum ALT and massive liver damage, indi-
cated by profuse PMN infiltration, necrosis, and apoptosis, were 
observed (Fig. 2, A and B). TUNEL assay and caspase 3 activity 
confirmed the severity of TRAIL-mediated apoptosis on 
NEMOhepa mice (Fig. 2, C and D). Previous work indicated 
that TRAIL induced JNK activation, leading to cellular apo-
ptosis (Herr et al., 1999). Accordingly, we found that TRAIL 
promoted strong JNK activation in NEMOhepa livers, whereas 
it remained inactive in NEMOf/f mice (Fig. 2 E). Moreover, 
TRAIL administration promoted a significant induction of 
TNF in NEMOhepa mice that was confirmed by IHC, uncov-
ering the Kupffer cells as its main source (Fig. 2 F). These results 
suggest that hepatocyte-NEMO deletion promotes hypersensi-
tivity to TRAIL-mediated apoptosis; hence, we next attempted 
to elucidate the potential mechanisms underlying this effect.
Interestingly, DR5 was highly expressed in livers of un-
treated NEMOhepa mice, where it was mainly present in   
hepatocytes (Fig. 2 G). This was confirmed in vitro, where 
NEMOhepa hepatocytes showed an eightfold increase in DR5 
expression and a complete inability to activate NF-B in re-
sponse to TRAIL in contrast to WT cells (Fig. S2, A and B). 
Accordingly with our in vivo data, WT cells remained unaf-
fected, whereas TRAIL induced JNK activation on hepato-
cytes lacking NEMO, leading to strong apoptotic cell death 
which was significantly abrogated by JNK inhibition with 
SP600125 (Fig. S2, C and D). The protection elicited by JNK 
inhibition, despite the absence of NF-B in NEMO-deficient 
hepatocytes, suggests an essential role of DR5-JNK signaling 
during TRAIL-induced cellular damage in NEMOhepa mice.
NK cells are the main producers of TRAIL in the liver 
(Smyth et al., 2001; Takeda et al., 2001). Earlier studies dem-
onstrated that genetically or dietary-induced fatty liver dis-
ease promotes activation of these cells (Guebre-Xabier et al., 
2000; Li et al., 2005). Thus, we hypothesized that similar   
alterations in the innate immune system might also arise in 
livers of NEMOhepa mice.JEM VOL. 206, August 3, 2009  1731
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Expression of the antiinflammatory cytokine IL-10, which 
negatively regulates TNF, IFN-, and IL-12 after ConA 
(Louis et al., 1997), was significantly lower in NEMOhepa, 
indicating their inability to orchestrate a proper antiinflamma-
tory response to ConA hepatitis (Fig. 4 D). As expected, up-
regulation of TNF was observed in WT and NEMOhepa 
Activated macrophages are the main producers of IL-12, 
which promotes NKT cell activation and further IFN- 
production (Trinchieri, 2003). This phenomenon may also   
occur in NEMOhepa mice, as IL12-p35 was significantly up-
regulated before ConA and was further increased following 
injury (Fig. 4 D).
Figure 2.  NEMOhepa mice are sensitive to low doses of TRAIL-mediated liver injury. 25 mg/kg of flagged TRAIL was administered i.v. (A) ALT  
serum levels were significantly elevated in NEMOhepa mice after TRAIL. (B–D) H&E staining (B), TUNEL assay (C), and caspase 3 activity (D) showed TRAIL-
mediated liver damage and apoptosis in NEMOhepa mice. (E) Western blot analysis showed JNK phosphorylation. JNK1 and GAPDH were used as loading 
controls. (F) RT-PCR analysis of TNF mRNA and IHC showed higher expression in NEMOhepa mice. (G) mRNA analysis and IHC evidenced strong DR5  
expression in NEMOhepa livers compared with NEMOf/f. Bars, 50 µm. All data are representative of three independent experiments. n = 4. **, P < 0.01;  
***, P < 0.001 (NEMOf/f vs. NEMOhepa). §§, P < 0.01; §§§, P < 0.001 (NEMOhepa vs. TRAIL/NEMOhepa). Error bars represent SD.1732 NEMO MODULATES LIVER NK/NKT CELL ACTIVATION | Beraza et al.
Figure 3.  Hepatocyte-specific deletion of NEMO promotes spontaneous activation of liver NK/NKT cells, and administration of NK1.1-
  depleting mAb attenuates the damaging phenotype in NEMOhepa mice. (A) FACS analysis revealed a lower number of NK1.1+CD3 and NK1.1+CD3+ 
cells in NEMOhepa mice. The graph represents the percentage of NK1.1+ cells related to the percentage of CD45+ cells in the liver (B) FACS analysis of 
NK1.1+/annexin V+ related to % of CD45+ cells revealed strong apoptosis of NK1.1+ cells in livers from NEMOhepa mice. (C) RT-PCR showed strong expres-
sion of IL-12 (p35), IFN-, and CCL5 but lower IL-4 mRNA in livers. Data are presented as times versus NEMOf/f untreated. (D) mRNA analysis of isolated 
NK1.1+ cells confirmed cell activation and increased cytokine expression. (E) FACS analysis showed stronger TRAIL expression on NK1.1+ cells from livers 
from NEMOhepa mice. mRNA analysis on isolated NK1.1+ cells confirmed this. (F and G) FACS analysis proved effective depletion of NK1.1+ cells (F) 40 h 
after NK1.1 mAb administration that reduced IFN- and CCL5 mRNA levels (G). (H–J) Serum ALT (H), H&E staining (I), and FACS analysis (J; CD11b+ cells) 
were used as markers of liver damage and inflammation. Bars, 50 µm. All data are representative of three independent experiments. n = 4. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001 (NEMOf/f vs. NEMOhepa). §§, P < 0.01 (NEMOhepa vs. Nk1.1mAb/NEMOhepa). Error bars represent SD.JEM VOL. 206, August 3, 2009  1733
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activity (Fig. 5 C). Accordingly, IFN-, CCL5, and IL-4   
levels were lower after ConA in NK1.1-depleted NEMOhepa 
mice (Fig. 5 D), and systemic IFN- and TNF serum levels 
were significantly reduced (Fig. 5 E). Remnant cytokine ex-
pression despite NK1.1 mAb is likely explained by the fact 
that ConA promotes activation of other cell compartments 
like macrophages.
mice after ConA but no significant differences were observed 
between genotypes (Fig. 4, D and E).
NK/NKT cell depletion lead to a remarkable improve-
ment of liver parenchyma, indicated by lower ALT, necrosis, 
inflammation, and infiltration of PMNs (Fig. 5, A and B). 
Attenuation of ConA induced liver apoptosis after NK1.1 
mAb treatment was confirmed by TUNEL assay and caspase 8 
Figure 4.  ConA promotes stronger liver damage in NEMOhepa mice than in NEMOf/f animals. (A–C) ALT serum levels (A), H&E staining and  
TUNEL analysis (B), and quantification of caspase 8 and 3 activity (C) measured 6 h after 25 mg/kg ConA showed strong liver damage in NEMOhepa mice.  
(D) mRNA levels of IFN-, IL-4, CCL5, IL-12p35, TNF, and IL-10. All RT-PCR data are presented as times versus NEMOf/f untreated. (E) ELISA of IFN- and 
TNF in serum before and 6 h after 25 mg/kg ConA. Bars, 50 µm. All data are representative of three independent experiments. n = 4. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001 (NEMOf/f vs. NEMOhepa). §§, P < 0.01; §§§, P < 0.001 (NEMOhepa vs. ConA/NEMOhepa). Error bars represent SD.1734 NEMO MODULATES LIVER NK/NKT CELL ACTIVATION | Beraza et al.
Figure 5.  NK1.1 cell depletion and adoptive transfer of TRAIL/ MNCs protects NEMOhepa mice against ConA-mediated fulminant hepati-
tis. (A–C) ALT serum levels (A), H&E staining (B), TUNEL analysis, and quantification of caspase 8 (C), 6 h after 25 mg/kg ConA revealed strong attenuation 
of ConA hepatitis in NEMOhepa mice when NK1.1 mAb was administered 40 h before insult. (D and E) mRNA levels of IFN-, CCL5, and IL-4 (D) and ELISA 
of IFN- and TNF (E) on serum confirmed attenuation of ConA damage in NEMOhepa mice after NK1.1 mAb. (F–H) Adoptive transfer of TRAIL/ MNCs JEM VOL. 206, August 3, 2009  1735
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and liver TRAIL/ NK1.1+ cells after NK1.1 mAb protected while TRAIL+/+ MNC transfer restored ConA injury in NEMOhepa mice as shown by serum ALT 
(F), H&E staining (G), and ELISA (H) of IFN- serum levels. (I) ConA-mediated JNK activation was attenuated by NK1.1 mAb and restored by TRAIL+/+ MNCs 
adoptive transfer. TRAIL/ cells maintained JNK inactivated. JNK1 and GAPDH act as loading control. Bars, 50 µm. All data are representative of three 
independent experiments. n = 4. **, P < 0.01; ***, P < 0.001 (NEMOhepa vs. ConA/NEMOhepa). §, P < 0.05; §§, P < 0.01; §§§, P < 0.001 (ConA/NEMOhepa vs. 
NK1.1mAb/ConA/NEMOhepa).
 
Recent work showing that TRAIL/ mice are protected 
from ConA-induced liver injury highlighted the important role 
of TRAIL in this model (Zheng et al., 2004). Thus, we exam-
ined if this cytokine may be an essential mediator of ConA liver 
damage in our NEMOhepa mice. We performed intrahepatic 
adoptive transfer of splenic mononuclear cells (MNCs) from 
TRAIL/ or TRAIL+/+ mice before ConA administration in 
NK1.1+-depleted mice. Liver damage was strongly attenuated 
in NEMOhepa mice receiving TRAIL/ MNCs in contrast to 
TRAIL+/+ MNC transferred mice, where injury was restored 
(Fig. 5, F and G). Additionally, adoptive transfer of TRAIL+/+ 
MNCs into NK1.1-depleted NEMOhepa mice restored both 
liver and systemic IFN- expression after ConA, whereas it re-
mained low in NEMOhepa mice receiving TRAIL/ MNCs 
(Fig. 5 H). The essential implication of NK cell–derived TRAIL 
in mediating ConA hepatitis in NEMOhepa mice was further 
confirmed by adoptive transfer of isolated NK1.1+ cells from 
TRAIL/ mice, which preserved liver protection against 
ConA injury elicited by NK1.1 mAb (Fig. 5, F–H).
During ConA-mediated hepatitis, JNK activation is related 
to the degree of apoptosis and the severity of the cellular stress 
(Trautwein et al., 1998). Additionally, we showed the detri-
mental effects of the TRAIL-JNK cascade in NEMOhepa mice 
both in vivo and in vitro (Fig. 2 and Fig. S2). Accordingly, 
strong JNK activation was observed in NEMOhepa mice after 
ConA, whereas it was clearly blunted after NK1.1 mAb despite 
ConA administration (Fig. 5 I). JNK activation was restored 
after adoptive transfer of TRAIL+/+ MNCs in NEMOhepa liv-
ers after ConA despite NK1.1 mAb treatment. On the contrary, 
transfer of both TRAIL/ MNCs and TRAIL/ NK1.1+ 
cells maintained the resistance of NK1.1-depleted NEMOhepa 
mice to ConA-mediated JNK activation (Fig. 5 I).
Previous studies using a NK1.1 mAb described that NKT 
cells are an essential cell subset responsible for ConA-medi-
ated liver injury as selective depletion of NK cells with an 
anti-asialo GM1 antibody had no impact on ConA hepatitis 
(Toyabe et al., 1997). However, our present data strongly 
support the hypothesis that NK cell–derived TRAIL plays a 
key role in the progression of ConA-induced liver damage in 
NEMOhepa mice. Accordingly, we observed that NK cell 
depletion with asialo-GM1 mAb significantly reduced ALT 
levels (2.17-fold; Fig. S4 A), a comparable effect to that ob-
served with NK1.1 mAb (Fig. 5 A; 2.56-fold reduction). Ac-
cordingly, hematoxylin and eosin (H&E) and TUNEL assay 
revealed significant protection against ConA after NK cell de-
pletion (Fig. S4, B and C), accompanied by reduced CCL5 in 
asialo-GM1–treated NEMOhepa mice. Interestingly, despite 
the clear protection elicited by NK cell depletion, we found 
high  IL-4  mRNA  expression  in  asialo-GM1  mAb–treated 
KOs (Fig. S4 D) suggesting remnant activation of NKT cells. 
Moreover, downregulation of serum IFN- levels supports 
the implication of this cytokine in the activation and produc-
tion of TRAIL from NK cells in an autocrine fashion (Smyth 
et al., 2001; Takeda et al., 2001). This data strongly supports 
the essential role of TRAIL-producing NK cells in mediating 
the dramatic impact of ConA on NEMOhepa mice.
Our present study uncovers a new mechanism by which 
hepatocyte-specific NEMO deletion contributes to spontane-
ous liver inflammation and injury. We show that NEMO de-
letion sensitizes the liver to TRAIL-mediated apoptosis and 
this contributes to disease progression. We propose a dual 
mechanism consisting of up-regulation of DR5 on hepato-
cytes and the activation of TRAIL-producing NK cells to 
cause the detrimental effects of NEMO deletion in the liver. 
The first mechanism is supported by studies showing that ste-
atosis  and  free  fatty  acids  promote  up-regulation  of  DR5 
mRNA expression (Malhi et al., 2007). Additionally, the pro-
fuse bile acid accumulation found in livers of NEMOhepa 
mice (unpublished data) may further promote DR5 expres-
sion (Higuchi et al., 2004). In addition to increased DR5 ex-
pression, fatty liver disease also triggers NKT cell activation, 
leading to a proinflammatory cytokine response (Li et al., 
2005), which we also observed in our NEMOhepa mice.
Additionally, it has been shown that NKT cells promote 
NK cell activation and TRAIL production through IFN- 
expression (Smyth et al., 2001). At present, the relevance of 
intestinal bacterial products transported into the liver through 
the blood stream and its role in NK and NKT cell activation 
is unclear in this model. However, this mechanism could also 
be relevant, as LPS induces macrophages to produce IL-12, 
triggering IFN- production by NKT cells in the absence of 
IL-4 (Dobashi et al., 1999; Guebre-Xabier et al., 2000). This 
scenario closely resembles the liver environment found in un-
treated NEMOhepa mice.
Our present work strengthens the essential role of hepato-
cyte NEMO/NF-B to maintain liver homeostasis because ab-
sence of NEMO in these cells activates the innate immune 
system, thus promoting liver damage. The cascade of molecular 
events leading from steatohepatitis to fibrosis and tumor devel-
opment observed in NEMOhepa mice reflects the pathogenesis 
of liver cirrhosis and HCC in humans. Further work in this 
model could yield novel therapeutic strategies targeting the NK 
cell/TRAIL axis to modulate chronic liver disease progression.
MATERIALS AND METHODS
Generation  of  hepatocyte-specific  conditional  NEMO  KO  mice. 
We generated mice carrying the loxP site–flanked (floxed [f]) NEMO gene 
(NEMOf/f) as described in detail in the supplemental figures. We generated 
NEMOhepa mice by crossing NEMOf/f with alfp-cre transgenic animals. For 1736 NEMO MODULATES LIVER NK/NKT CELL ACTIVATION | Beraza et al.
Online supplemental material. Fig. S1 shows the gene-targeting strategy 
for the generation of hepatocyte-specific NEMO KO mice. Fig. S2 demon-
strates the effect of TRAIL on primary hepatocytes. Fig. S3 shows the sur-
vival curve after ConA treatment. Fig. S4 shows the effects of asialo-GM1 
mAb administration during ConA hepatitis. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20082152/DC1.
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